NTLA: The 12% Genetic Risk Threatening CRISPR's Cure
NTLA stock targets 1,502% potential upside — CRISPR valuation buy or sell analysis
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Intellia Therapeutics (NTLA) and its strategic transition from a clinical-stage research entity into a commercial biopharmaceutical business. With revenue projected to grow 130% YoY to $120.3 million by FY 2027, the key question for investors is whether its one-time gene-editing therapies…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.